Andrew Lee

Andrew Lee has been working in the venture capital and biotechnology industries since 2019. Andrew began their career as a Principal at Northpond Ventures, a leading global science, medical, and technology-driven venture firm. In 2021, they became a Board Director at Culture Biosciences and a Board Observer at Refeyn, Slingshot Biosciences, and Isolere Bio. In 2022, they joined EnPlusOne Biosciences as a Board Director and became a Board Observer at 64x Bio, Ansa Biotechnologies, Inc., and Sound Agriculture. Andrew is currently employed at Sherlock Biosciences as a Board Observer.

Andrew Lee attended Columbia University from 2010 to 2016, where they earned a Doctor of Philosophy (Ph.D.) in Microbiology. Prior to that, they attended the University of California, Berkeley from 2005 to 2009, where they earned a Bachelor's Degree in Biochemistry and Molecular Biology.